FDA slaps China-based API makers with separate warning letters outlining quality, testing shortfalls
A pair of Chinese manufacturers with active pharmaceutical ingredients that were previously shipped to the U.S. | The FDA ...
So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...
New Hampshire’s Bio X Cell, which has made a name for itself over the past quarter-century cranking out functional antibodies ...
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as ...
Bayer is worried about your heart health. | Older millennials, take note: Bayer is worried about your heart health. The drugmaker set out its concerns in an ad for aspirin, showing how people are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback